Impact of China's Diagnosis-Intervention Packet Policy on Hospitalization Costs for Patients With Malignant Tumors: A 2019-2022 Interrupted Time Series Analysis

中国诊疗一体化政策对恶性肿瘤患者住院费用的影响:2019-2022年中断时间序列分析

阅读:1

Abstract

PURPOSE: China's diagnosis-intervention packet (DIP) policy, a medical insurance payment system leveraging big data, was implemented in Wuhu, China, in January 2021. Studies have proven that the DIP has been effective in reducing medication costs for elderly hospital patients with hypertension. However, research on hospitalization costs for other patients remains limited. As the incidence of malignant tumors has increased dramatically in China, this study assesses the system's impact on hospitalization costs for patients with malignant tumors to confirm its broader effects. PATIENTS AND METHODS: Data on patients with malignant tumors (ICD codes C00-C97) were collected from a tertiary medical institution in Wuhu, using the policy's implementation in January 2021 as the beginning timepoint. Outcome indicators included average monthly hospitalization expenses and sub-expenses for hospitalized patients with malignant tumors. A 48-month time-series database was constructed and the interruption time series model used to evaluate the changing trends in expenses before and after the DIP implementation. RESULTS: After DIP implementation, average hospitalization costs for patients with malignant tumors showed a statistically significant downward trend. Subgroup analysis revealed that patients with shorter hospital stays (1-5 days) and cured outcomes saw the biggest expense drop from hospital cost-control effects. The DIP policy also affected cost structures, initially increasing diagnostic fees and consumable costs, but significantly reducing treatment fees, medication costs, and other related costs. CONCLUSION: The study confirmed the effectiveness of the DIP policy in controlling hospitalization costs for patients with malignant tumors. Going forward, the government should optimize DIP rules to clarify cost calculation methods and prevent excessive use of high-cost diagnostics and consumables. Continued monitoring and evaluation are essential to ensure that the policy's benefits are maintained over time. Medical institutions should improve resource allocation, diagnosis, and treatment efficiency; reduce unnecessary stays; and provide tailored treatment plans and cost support for patients with poor prognosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。